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Abstract
Objective: Recently it has been shown that there is not
only endocrine insufficiency in diabetic patients, but a
frequent co-morbidity of both, the endocrine and ex-
ocrine pancreas. The present study was performed to
further analyse the determinants of exocrine pancreat-
ic function in patients with diabetes mellitus.
Methods: The records of 1992 patients with diabetes
mellitus who had been treated in our hospital during a
2-year period were re-evaluated. Defined parameters
were documented in standardized data sheets. Records
were further checked for the results of imaging proce-
dures of the pancreas. In 307 patients FEC had been
performed and documented. Only these patients were
included in further evaluation.
Results: FEC was inversely correlated with diabetes
duration and HbA1c-levels but not with age. C-pep-
tide levels correlated positively with FEC. BMI and
FEC were also significantly correlated. There was no
correlation between diabetes therapy and exocrine
pancreatic function as there was no correlation with
any concomitant medication. The presence of dia-
betes-associated antibodies was not related to FEC.
According to the documented data 38 were classified
as type-1 diabetes (12.4%), 167 as type-2 (54.4%), and
88 patients met the diagnostic criteria of type-3
(28.7%). Fourteen patients could not be classified be-
cause of lacking information (4.6%).
Conclusions: Exocrine insufficiency might be ex-
plained as a complication of diabetes mellitus. Howev-
er, it is more likely that type-3 diabetes is much more
frequent than previously believed. Consequently the
evaluation of exocrine function and morphology
should be included into the clinical workup of any dia-
betic patient at least at the time of manifestation.
Key words: diabetes mellitus, exocrine pancreatic func-
tion, fecal elastase, type 3 diabetes
INTRODUCTION
As a consequence of the close anatomical and physio-
logical proximity of exocrine and endocrine pancreas,
exocrine pancreatic morphology and function have
been studied in patients with diabetes mellitus in nu-
merous studies. Dating back to 1943 [1] and during
the following decades direct function tests (e.g. se-
cretin-test and modifications) have been used for this
purpose and a prevalence of 43-80% of exocrine in-
sufficiency has been reported in patients with insulin
dependent diabetes mellitus (IDDM) [2-6]. Since the
use of direct function tests is rather invasive and in-
convenient these studies have been limited to rather
small numbers of patients.
In 1992, the measurement of fecal elastase-1 con-
centrations (FEC) by means of an ELISA based on
monoclonal specific antibodies was suggested as a new
indirect test of exocrine pancreatic function [7] and
became commercially available (ScheBo Biotech,
Giessen, Germany). This test was validated in compar-
ison with direct function tests and results of imaging
procedures. It proofed to be sensitive in moderate and
severe pancreatic insufficiency and it correlated with
pancreatic duct changes in ERCP images [8, 9]. De-
spite some critical comments [10, 11] it has become a
standard test for indirect measurement of exocrine
function during the last years for its clinical usefulness
[12, 13]. Utilising this non-invasive test, it became pos-
sible to screen larger patient groups and several stud-
ies used it to investigate larger populations of both,
patients with type-1 and type-2 diabetes mellitus.
These studies included up to 1000 patients and report-
ed a high prevalence in both, type-1 (50-60%) [14, 15,
16] and type-2 diabetes (35-40%) [14, 16, 17]. Summa-
rizing the results of direct and indirect tests there can
be no doubt that exocrine pancreatic insufficiency is
very frequent in patients with diabetes mellitus. Addi-
tionally, there have been a number of reports on mor-
phologic changes of the exocrine pancreas (atrophy,
fibrosis, chronic pancreatitis) including histology, ul-
trasound, CT and ERCP [18-23].
Therefore it has to be noticed that there is not only
endocrine insufficiency in diabetic patients, but a fre-
quent co-morbidity of both, exocrine and endocrine
pancreas.
A number of hypothesis have been raised to explain
these findings: exocrine pathology might be a result of
local insulin deficiency or neuropathic changes in dia-
betes mellitus. The prevalence of type-3 diabetes
might be higher than believed previously or autoim-
mune diseases could involve both parts of the gland.
While the relevance of these hypotheses is still under
debate, some recent studies observed that there is a
correlation between FEC and residual beta cell func-
tion, quality of diabetes control [24] and diabetes du-
ration [16] suggesting exocrine dysfunction to be a
complication of diabetes mellitus. Since the arguments
have not been convincing so far, we decided to re-eval-
uate the records of patients having been hospitalized
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tion during a 2 year period (01.01.2003-31.12.2004)
concerning diabetes classification, diabetes associated
parameters and exocrine pancreatic function.
METHODS AND STATISTICS
The records of 1992 patients with diabetes mellitus
who had been hospitalized and treated in our institu-
tion during a 2 year period (01.01.2003-31.12.2004)
were re-evaluated. Defined parameters were docu-
mented in standardized data sheets.
The parameters comprised data of patients´ history
(diabetes duration, diabetes therapy, complications,
concomitant therapy and other diseases e.g. celiac dis-
ease) and clinical symptoms related to diabetes and the
GI-tract. Laboratory markers included diabetes associ-
ated antibodies, other immunological markers, HbA1c,
C-peptide levels, fecal elastase-1 concentrations (FEC).
Records were further checked for the results of imag-
ing procedures of the pancreas (ERCP, MRT, Ultra-
sound, CT).
In 307 patients FEC had been performed and docu-
mented. Only these patients were included in further
evaluation.
The diabetes type was reclassified according to the
classification of the American Diabetes Association
[25] on the basis of the parameters available. Type-1
diabetes was diagnosed, if diabetes associated antibod-
ies were present and patients were insulin dependent
at diagnosis. Patients with high C-peptide levels and
BMI >25 kg/m2 without antibodies were classified as
type-2. Type-3 diabetes was diagnosed in patients
when exocrine pancreatic insufficiency and pathologic
imaging results were available in the absence of dia-
betes associated antibodies.
For statistical analysis SPSS V11.5 was used. Data
analysis included mean, median and standard devia-
tions. Kolmogorov-Smirnov-test was used to test
Gaussian distribution. Pearson-test or Spearman-Rho-
test was used to investigate correlations between di-
verse parameters.
RESULTS
In 307 patients FEC were available. These were in-
cluded to further evaluation. Of these, 138 were fe-
male (45%) and 169 male (55%). According to the
data documented in the files, 38 were classified as
type-1 diabetes (12.4%),167astype-2diabetes (54.4%),
and 88 patients met the diagnostic criteria of type-3
diabetes (28.7%). Fourteen patients could not definite-
ly be classified because of lacking information (4.6%).
The mean age was younger in type-1 patients and
similar in types 2 and 3 (Table 1).
Diabetes duration, HbA1c- and C-peptide levels in
the different types of diabetes are shown in Table 1.
Patients classified as type-2 diabetes had the shortest
duration of the disease, higher C-peptide levels and
better glycemic control than type-3 and type-1 pa-
tients. FEC are shown in Table 2, the prevalence of
exocrine insufficiency in different diabetes types is
shown in Figure 1. FEC did slightly decrease with age,
but this was not statistically significant (Fig. 2). Obvi-
ously pancreatic exocrine insufficiency (PEI) was more
frequent in type-3 diabetes because this made part of
the definition. However, there were also several cases
of PEI in the other diabetes types. FEC was inversely
correlated with diabetes duration (p = 0.004, Fig. 3)
and HbA1c-levels (p = 0.031, Fig. 4). C-peptide levels
correlated positively with FEC (p<0.001, Fig. 5). BMI
and FEC were also significantly correlated (p = 0.042,
Fig. 6). There was no correlation between diabetes
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Table 1. Patients`characteristics concerning age, diabetes du-
ration, HbA1c and C-peptide-levels.
Diabetes- Age (years)
type Mean Median Minimum Maximum
Type-1 41.8 42 14 75
Type-2 59.8 62 32 84
Type-3 60.5 62 21 83
Diabetes Duration (years)
Type-1 11.8 9 0.0 52
Type-2 7.9 5 0.0 36
Type-3 11.5 9 0.5 37
HbA1c (%)
Type-1 8.3 85 14.5
Type-2 7.4 6.9 4.2 14.5
Type-3 7.9 7.8 4.8 13.4
C-Peptide (µg/l)
Type-1 1.1 1.1 0.0 4.1
Type-2 3.2 2.7 0.5 7.6
Type-3 2.1 1.9 0.5 5.9
Table 2. Fecal Elastase-1 concentrations (FEC) in 307 pa-
tients.
Diabetes- FEC (µg/g)
type n Mean Median Minimum Maximum
Type-1 38 326.4 383.5 0 685
Type-2 167 396.5 395 0 826
Type-3 88 94.4 94 0 199
Not 14 200.5 143 37 761
classified
Sum 307 292.3 265 0 826
Fig. 1. Number of patients with exocrine insufficiency as
measured by fecal elastase-1 concentrations (FEC)
5. Ewald neu:Umbruchvorlage  23.02.2009  16:13 Uhr  Seite 119therapy and exocrine pancreatic function as there was
no correlation with any concomitant medication. The
presence of diabetes-associated antibodies was not re-
lated with FEC. Other immunological markers (e.g.
thyroid or celiac disease) had been evaluated only in a
minority of patients, therefore statistical analysis ap-
peared not to be reasonable.
DISCUSSION
Summarizing the results of functional and morpho-
logical studies of the exocrine pancreas in patients
with diabetes mellitus, it has to be noticed that there is
not only exocrine insufficiency in diabetic patients, but
a frequent co-morbidity of both, exocrine and en-
docrine pancreas [1-24].
This could be explained in part by the assumption
that pancreatic diabetes mellitus (type-3) must be more
frequent than previously believed [4, 14, 16]. In the
general opinion type-3 diabetes has been described to
account for about 1% of diabetics [26]. These estima-
tions dating back to the 1960s and 1980s have proba-
bly been biased because the evaluation of the exocrine
pancreas had been limited due to highly invasive pro-
cedures (direct function tests, ERP). However, since
indirect function tests, ultrasound, CT and MRT made
it easier to asses function and morphology of the ex-
ocrine portion of the gland, it has been used more fre-
quently and a higher prevalence of type-3 diabetes ap-
pears to be reasonable. Reclassifying the patients of
the present study according to the suggestions of the
American Diabetes Association [25] on the basis of
the data documented in the patients charts, we found
that in our population type-3 diabetes was even more
common than type-1 patients. Of course there must
be a certain bias, because exocrine pancreatic function
had only been evaluated in 307 out of 1992 patients
and it was not part of the standard evaluation pro-
gram for diabetic patients. Therefore it is likely that
FEC testing has been done rather in patients with a
suspicion of exocrine disease than in others. However,
even if all patients not being tested for exocrine func-
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Fig. 2. Fecal elastase-1 concentrations depending on age and
gender.
Fig. 3. Fecal elastase-1- concentrations (FEC)
and diabetes duration.
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sified as type-3 by morphological and functional find-
ings the percentage of pancreatic diabetes within 1992
patients would still be 4.2%. This is a remarkable find-
ing, since the treatment of type-3 diabetes bears some
peculiarities different from other diabetes types.
It has also been claimed that local insulin deficiency
and a loss of the trophic insulin effects on surround-
ing beta cells could explain the finding of pancreas at-
rophy at least in patients with type-1 diabetes. While
most of the older studies did not describe correlations
between exocrine pancreatic function and residual beta
cell activity or diabetes duration there have been re-
ports on this more recently [16, 24]. In the present
study we also observed declining concentrations of fe-
cal elastase-1 with diabetes duration but not with age.
Furthermore, C-peptide levels were correlated posi-
tively. Thus exocrine insufficiency might also be ex-
plained as a complication of diabetes mellitus.
To learn more about the clinical relevance of type-3
diabetes mellitus and the pancreatic complications of
diabetes mellitus future studies should prospectively
investigate exocrine pancreatic function in patients di-
agnosed with diabetes mellitus. At present is seems to
be reasonable for the clinical workup to evaluate ex-
ocrine function and morphology in any diabetic pa-
tient at least at the time of diabetes manifestation.
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Fig. 6. Fecal elastase-1- concentrations (FEC)
and Body Mass Index (BMI).
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